Antiphospholipid antibodies (aPL) are frequently detected in immune thrombocytopenia (ITP) and whether they play a role in ITP prognosis is controversial. Previous studies have shown that aPL positivity may not be associated with either platelet counts or response to treatment [1–4]; however, heterogeneity in the classification of ITP outcomes and high variability of aPL assays performed across studies may affect results consistency.
